Zevra Therapeutics, Inc. (ZVRA)
Nasdaq: ZVRA · Pharmaceutical Preparations · Boston, MA · filing with the SEC since 2008
Who owns Zevra Therapeutics, Inc.
As filed with the SECHolders of 5% or more
4
Fmr LLC holds 8.3% of COMMON STOCK, as its SCHEDULE 13G/A filed Aug 6, 2026 says.
Directors and officers
14
report now, of 27 people on the record since 2015. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 4 named at left.
Holders of 5% or moreshare of the class, as filed
Fmr LLC
SCHEDULE 13G/A · filed Aug 6, 2026 · COMMON STOCK · 5.5% in May 6, 2026
Woodline Partners LP
SCHEDULE 13G/A · filed Aug 14, 2026 · Common Stock, par value $0.0001 per share · 6.2% in Nov 14, 2025
Blackrock, Inc.
SCHEDULE 13G/A · filed Feb 5, 2025 · Common Stock
Vanguard Capital Management
SCHEDULE 13G · filed Jul 31, 2026 · Common Stock
Nantahala Capital Management, LLC
SCHEDULE 13G/A · filed Feb 14, 2025 · Common Stock, $0.0001 par value per share · reported falling below 5%, from 5.56% in Nov 14, 2024
Adage Capital Management, L.P.
SCHEDULE 13G/A · filed Nov 13, 2025 · Common Stock, par value $0.0001 per share · reported falling below 5%, from 6.84% in Feb 12, 2025
The Vanguard Group
SCHEDULE 13G/A · filed Mar 27, 2026 · Common Stock · reported falling below 5%
What ZVRA reports owning in othersstakes of 5% or more, and other ties
Other ties the annual report names
Olpruva
A company bought · acquisition · owns, named in the 10-K filed Mar 9, 2026
1 subsidiary in 1 country, from the list filed with the 10-K filed Mar 9, 2026.
Insider tradesForm 4
13sales
0purchases
12sales on a scheduled plan
6people selling
$2.5Msold, in dollars
$0bought, in dollars
Open-market trades on Form 4 from Oct 13, 2025 to Oct 13, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2026 runs to Oct 13, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window6 of 33 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| Mcfarlane Neil F. | President and CEO | 3 | $1.2M | 3 | 0 | $0 |
| Thompson Rahsaan | Chief Legal & Compliance | 4 | $1.0M | 4 | 0 | $0 |
| Schafer Joshua | CCO | 2 | $100,000 | 2 | 0 | $0 |
| Watton Corey Michael | director | 1 | $100,000 | 0 | 0 | $0 |
| Quartel Adrian W | Chief Medical Officer | 1 | $0 | 1 | 0 | $0 |
| Sangiovanni Timothy J. | SVP, Finance & Corp Controller | 2 | $0 | 2 | 0 | $0 |